<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>MMSI Stock Falls Despite CE Mark Win for Embosphere in Knee OA Care — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">MMSI Stock Falls Despite CE Mark Win for Embosphere in Knee OA Care</h2>
    <div class="badge">2025-09-15T16:34:00+00:00</div>
    <ul>
      <li>West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%.</li>
<li>Medpace Holdings, sporting a Zacks Rank of 1, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%.</li>
<li>Revenues of $603.3 million outpaced the consensus mark by 11.5%.</li>
<li>Revenues of $682 million surpassed the Zacks Consensus Estimate by 6.3%.</li>
<li>Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%.</li>
<li>Envista reported second-quarter 2025 adjusted EPS of 26 cents, which beat the Zacks Consensus Estimate by 8.3%.</li>
<li>Favorable Industry Prospects for MMSI Per a report by Grand View Research, the global osteoarthritis therapeutics market size was estimated at $9.13 billion in 2024 and is projected to reach $13.57 billion by 2030, regis</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=MMSI Stock Falls Despite CE Mark Win for Embosphere in Knee OA Care\n• West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%.\n• Medpace Holdings, sporting a Zacks Rank of 1, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%.\n• Revenues of $603.3 million outpaced the consensus mark by 11.5%.\n• Revenues of $682 million surpassed the Zacks Consensus Estimate by 6.3%.\n• Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%.\n• Envista reported second-quarter 2025 adjusted EPS of 26 cents, which beat the Zacks Consensus Estimate by 8.3%.\n• Favorable Industry Prospects for MMSI Per a report by Grand View Research, the global osteoarthritis therapeutics market size was estimated at $9.13 billion in 2024 and is projected to reach $13.57 billion by 2030, regis" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/mmsi-stock-falls-despite-ce-163400406.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>